Login to Your Account

Heparegenix's series A to support work on 'EPO for the liver'

By Nuala Moran
Staff Writer

Thursday, January 5, 2017

LONDON – Heparegenix GmbH has raised €9 million (US$9.4 million) in a series A to advance a new approach to treating liver diseases into the clinic, with non-alcoholic steatohepatitis as the first indication to be targeted.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription